EUVIMEDEUVIMED entdecken
Crossref

Evaluation of the Relationship between FeNO and Clinical Risk Stratification for Early Mortality in Pulmonary Embolism

Bugra Kerget, Hatice B Ozkan, Elif Y Ucar, Leyla Saglam

Clinical Laboratory · 2023 · 69 (11/2023)

DOI: 10.7754/clin.lab.2023.230402 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Laboratory, 2023. Verfasst von Bugra Kerget und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Fractional Exhaled Nitric Oxide Testing, Pulmonary Embolism. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pulmonary embolism (PE) is a common complication of deep vein thrombosis that causes high mortality and morbidity. This study aimed to determine the relationship between clinical risk scoring for early mortality and fractional exhaled nitric oxide (FeNO) in PE patients. METHODS: The study included a total of 98 subjects, 68 patients diagnosed with PE in the emergency department, and 30 healthy controls. Patients with PE were grouped according to clinical scoring of early mortality risk as low (n = 20), moderate-low (n = 24), and moderate-high (n = 24) risk. FeNO levels were measured after diagnosis. RESULTS: FeNO levels were significantly higher in patients with moderate-high risk PE compared to the other three groups and in those with moderate-low risk PE compared to the control group (p < 0.001 for all). Moderate to strong positive correlations were observed between FeNO level and mean pulmonary artery pressure (r = 0.818, p = 0.01), troponin-I (r = 0.67, p = 0.01), pro-BNP (r = 0.762, p = 0.01), and D-dimer levels (r = 0.652, p = 0.01). A FeNO cutoff value of 7.5 ppb had 84% sensitivity and 78% specificity in differentiating moderate-high risk PE from moderate-low risk PE. CONCLUSIONS: FeNO may be as reliable, noninvasive, and easily accessible as cardiac biomarkers in clinical risk scoring for early mortality in PE patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fractional Exhaled Nitric Oxide TestingPulmonary EmbolismHumansNitric OxideBreath TestsRisk AssessmentBiomarkers

Substanzen

Nitric OxideBiomarkers

Zitieren

APA

Kerget, B., Ozkan, H. B., Ucar, E. Y., & Saglam, L. (2023). Evaluation of the Relationship between FeNO and Clinical Risk Stratification for Early Mortality in Pulmonary Embolism. Clinical Laboratory, 69(11/2023). https://doi.org/10.7754/clin.lab.2023.230402

Vancouver

Kerget B, Ozkan HB, Ucar EY, Saglam L. Evaluation of the Relationship between FeNO and Clinical Risk Stratification for Early Mortality in Pulmonary Embolism. Clinical Laboratory. 2023;69(11/2023). doi:10.7754/clin.lab.2023.230402

BibTeX
@article{Kerget2023,
  author = {Kerget, Bugra and Ozkan, Hatice B and Ucar, Elif Y and Saglam, Leyla},
  title = {Evaluation of the Relationship between FeNO and Clinical Risk Stratification for Early Mortality in Pulmonary Embolism},
  journal = {Clinical Laboratory},
  year = {2023},
  volume = {69},
  number = {11/2023},
  doi = {10.7754/clin.lab.2023.230402}
}
Kostenlos starten →